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Excess neural activity in the CA3 region of the hippocampus has been linked to memory impairment in aged rats. We tested whether
interventions aimed at reducing this excess activity would improve memory performance. Aged (24 to 28 months old) male Long–Evans
rats were characterized in a spatial memory task known to depend on the functional integrity of the hippocampus, such that aged rats
with identified memory impairment were used in a series of experiments. Overexpression of the inhibitory neuropeptide Y 13–36 in the
CA3 via adeno-associated viral transduction was found to improve hippocampal-dependent long-term memory in aged rats, which had
been characterized with impairment. Subsequent experiments with two commonly used antiepileptic agents, sodium valproate and
levetiracetam, similarly produced dose-dependent memory improvement in such aged rats. Improved spatial memory with low doses of
these agents was observed in both appetitve and aversive spatial tasks. The benefits of these different modalities of treatment are
consistent with the concept that excess activity in the CA3 region of the hippocampus is a dysfunctional condition that may have a key
role underlying age-related impairment in hippocampal-dependent memory processes. Because increased hippocampal activation occurs
in age-related memory impairment in humans as observed in functional neuroimaging, the current findings also suggest that low doses of
certain antiepileptic drugs in cognitively impaired elderly humans may have therapeutic potential and point to novel targets for this
indication.
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Aging is often associated with a decline in memory
functions that depend on the hippocampus. Recent research
on neurocognitive aging has focused on localized increased
neural activity that may drive dysfunction underlying
memory impairment in the hippocampal network (Wilson
et al, 2006). Excess neural activity in the CA3 region of the
hippocampus occurs in aged rats with memory impairment
when such neurons are unable to encode new information
in a manner usually observed in young rats (Wilson et al,
2003, 2005). The current research was designed to test
the functional significance of such excess activity on
behavioral performance in hippocampal-dependent spatial
memory tasks.
Specialized functions of the subregions of the hippocam-
pus have recently elucidated a critical role for the CA3/
dentate gyrus in the encoding of information. When young
rats first explore a familiar arena and then are placed in a
novel environment, CA3 cells with location-specific encod-
ing (eg, place fields) rapidly form different patterns of
spatial encoding for the two environments (Leutgeb et al,
2004, 2007). In aged rats, on the other hand, hippocampal
CA3 neurons can have very similar spatial representations
across environments (Wilson et al, 2003, 2005). Hence,
rather than creating a new representation for a novel
environment, aged rats tend to retrieve a previously
stored representation, a process known as ‘pattern comple-
tion’, distinguishing it from ‘pattern separation’. Further-
more, the extent of this failure to encode new information
predicts the degree of spatial learning impairment (Wilson
et al, 2003). This positive correlation between behavior
and physiology supports the idea that the encoding
failure of hippocampal CA3 neurons contributes to im-
paired performance in settings that depend on spatial
memory. The concurrent localization of excess activity
in the CA3 population of pyramidal neurons also suggests
a dysfunctional role for such elevated firing rates, which
may shift the computational properties of this network
(Wilson et al, 2006).
We tested whether treatments aimed at reducing
excess neuronal activity in aged rats would improve
memory performance. Boosting neuropeptide Y (NPY)
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neurotransmission, especially through Y2 receptors, has
been shown to effectively attenuate neuronal excitability in
seizure models (Foti et al, 2007; Morris et al, 2007),
indicating a potential application to reduce elevated activity
associated with neurocognitive aging. Hence, we first
examined whether increasing NPY Y2 receptor activation
via adeno-associated virus (AAV) delivered into the CA3 of
the hippocampus would improve memory in cognitively
impaired aged rats. We then tested two different pharma-
cological agents that are widely used antiepileptic agents,
sodium valproate (VPA) and levetiracetam (LEV). In each
case, improved behavioral performance was produced by
these treatments in aged rats with identified cognitive
impairment, suggesting that excess neural activity in the
CA3 region contributes to behavioral memory deficits.
A test of LEV in young adult rats showed no such benefit,




Aged, male Long–Evans rats were obtained at 8 to 9 months
of age from Charles River Laboratories (Raleigh, NC) and
housed in a vivarium at Johns Hopkins University until 24
to 26 months of age. Young rats obtained from the same
source were housed in the same vivarium and tested at 6
months of age. All rats were individually housed at 251C and
maintained on a 12 h light/dark cycle. Food and water were
provided ad libitum unless noted otherwise. The rats were
examined for health and pathogen-free status throughout
the experiments, as well as necropsies at the time of killing.
All procedures in the current investigations were approved
by the Institutional Animal Care and Use Committee in
accordance with the National Institutes of Health directive.
Background Behavioral Characterization
All rats were screened in a standardized assessment of
spatial cognition before the studies with experimental
treatments. The background assessment used a well-
established Morris water maze protocol as described in
detail elsewhere (Gallagher et al, 1993). Briefly, the rats were
trained for 8 days (three trials per day) to locate a
camouflaged escape platform that remained at the same
location throughout training in a water maze. Every sixth
trial consisted of a probe trial (free swim with no escape
platform) that served to assess the development of a
spatially localized search for the escape platform. During
these probe trials, a learning index was generated from the
proximity of the rat to the escape platform and was used to
define impairment in the aged rats. The learning index is
the sum of weighted proximity scores obtained during
probe trials, with low scores reflecting a search near the
escape platform and high scores reflecting searches farther
away from the platform (Gallagher et al, 1993). Cue training
(visible escape platform) occurred on the last day of
training to test for sensorimotor and motivational factors
independent of spatial learning. Aged rats with impaired
spatial memory performance (ie, those with learning index
scores outside the young ‘normative’ range) but successful
cued training performance were used for the studies as
described below.
Surgery and Treatments
In the NPY experiment, memory-impaired aged rats were
assigned to either NPY or control treatment (n¼ 6 per
group), with group assignment matched for learning index
scores in the background characterization. The rats were
injected with either an AAV vector that expresses and
constitutively secretes NPY 13–36 (targeting Y2 receptors)
or control substances (AAV–GFP or saline) bilaterally into
the CA3 area of the hippocampus (2 ml per side). That
surgery, performed under isoflurane anesthesia, occurred
2 weeks before further behavioral assessment. Stereotaxic
coordinates were 3.6 mm posterior to bregma, 3.0 mm
lateral to midline, and 3.8 mm ventral to the skull surface.
AAV–NPY 13–36 vector contained a chicken b-actin (CBA)
promoter driving expression of a fragment of the NPY gene
encoding amino acids 13–36 fused to the fibronectin signal
sequence (FIB–NPY 13–36). The addition of the fibronectin
signal sequence results in constitutive, unregulated secre-
tion of NPY 13–36 protein from the transduced cells.
Although the FIB–NPY 13–36 mRNA is readily detected, the
secreted protein degrades rapidly making immunohisto-
chemical detection difficult (Haberman et al, 2003). The
AAV–GFP control vector contained the CBA promoter
driving enhanced green fluorescent protein. AAV virus was
made using standard procedures (Foti et al, 2007). All virus
titers were approximately 1 1012 particles per ml.
In an initial VPA experiment, memory-impaired aged rats
were implanted subcutaneously in the intrascapular region
with osmotic mini-pumps (ALZET, Durect, Cupertino, CA)
with VPA (50 or 100 mg/kg/day; Sigma-Aldrich, St Louis,
MO) or saline vehicle starting 2 weeks before the interven-
tion experiments. The VPA treatment at 100 mg/kg/day via
osmotic mini-pump was determined to produce a mean
total VPA concentration of 10 mg/ml (SEM¼ 1.28; n¼ 20) in
the plasma of aged rats, a level that agrees with those
reported by others when similar dosing with VPA was also
chronically administered via osmotic mini-pumps (Stout
et al, 2001). Other behavioral experiments used acute
administration of VPA or LEV (Sigma-Aldrich or Tecoland,
Edison, NJ) given by systemic injection 30–40 min before
test sessions.
Behavioral Assessment in the Water Maze
Rats were trained and tested in a novel water maze
environment to assess the effect of the treatments. The
water maze used here was housed in a different building and
was surrounded by curtains with a novel set of patterns
relative to the maze used for initial assessment of cognitive
status. The training protocol used in the NPY experiment
and in an assessment of LEV consisted of six trials per day
for 2 days to locate a submerged escape platform. On each
trial, a rat was released in the maze from one of four equally
spaced starting positions around the perimeter of the pool.
The starting position varied from trial to trial. If the rat did
not locate the escape platform within 60 s on any trial, the
experimenter guided and placed the rat on the platform,
where it remained for 20 s. The rat was then removed from
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the platform and placed in a holding cage for another 40 s
before the next trial. Approximately 24 h after the last
training trial, a probe test in the absence of the escape
platform was given to assess spatial memory.
The training protocol for the VPA experiment in the
water maze was based on a modified water maze task that
has been shown to be hippocampal-dependent (de Hoz
et al, 2005; Steele and Morris, 1999). Unlike the traditional
water maze protocol (such as that used in the background
assessment and the NPY and LEV experiments) wherein the
escape platform location remained constant throughout
training, the escape platform location in this version of the
task varied from day to day. During each day’s training
session, rats were given six trials to locate the submerged
escape platform. At the end of the training session, the rats
were returned to their home cages. After a 6-h delay, the
rats were returned to the water maze for a retention trial
with the submerged platform located in the same position as
in the previous session of training trials. Each rat was given
60 s to locate the platform. Rats were pretrained on this
protocol for 2 days, and then trained and tested in this
manner for 3 consecutive days. Performance on these 3 days
was averaged for analysis using the escape latency and path
to locate the platform as measures of retention; spatial bias
in a free swim was not used because the repeated training
protocol encourages rats to search for a new location when
escape is not readily achieved.
Behavioral Assessment in the Radial Arm Maze
A radial arm maze task was used to assess effects of acute
drug treatment with LEV, VPA, and the combination of
those drugs. This protocol allowed within-subject assess-
ment across drugs at different doses and in combinations.
The radial maze consisted of eight arms projecting from
each side of an octagonal center platform, with food well
located at the distal end of each arm. Plexiglas blocks could
be positioned to prevent entry into any arm. Extra-maze
cues were provided in the room surrounding the maze and
illumination was provided by an overhead light.
Pre-training, as described in detail in Chappell et al
(1998), consisted of habituation, standard win-shift train-
ing, and win-shift training with delays interposed between
information and memory test phases. Drug treatments
began 2 days after the completion of pre-training. Three
arms were blocked at the beginning of each trial (informa-
tion phase). The identity and configuration of the blocked
arms varied across trials. Food-deprived rats were allowed
to retrieve food reward (Kellogg’s Froot Loops cereal) from
the five unblocked arms. The rat was then removed from the
maze for 60 min (retention interval), during which time the
barriers on the blocked arms were removed allowing access
to all eight arms. Rats were then placed back onto the center
platform and allowed to retrieve the remaining food
rewards (memory test phase). An error consisted of
returning to an arm (all four paws on the arm) from which
food had already been obtained. Memory-impaired aged
rats (n¼ 10) were first tested with a series of LEV doses in
ascending/descending order; each dose was thus tested
twice, with one washout day in between each determination.
At the completion of LEV assessment, the same rats (n¼ 9,
because one rat died) were tested with a series of VPA doses
in the same fashion as that for LEV assessment with
performance at each dose tested twice. About a week after
the completion of the individual drug assessments, the rats
were given combination drug dosing in which ineffective
doses of LEV and VPA in monotherapy were administered
in combination (n¼ 8, one rat had to be dropped because of
health deterioration). The number of errors made in the
retention phase after the 1-h delay was used to assess
memory performance.
To determine whether treatment efficacy is age specific,
young rats (n¼ 8) were tested with varying doses of LEV in
the same fashion as that in the aged rats, except that a 5-h
retention interval was used to approximate the number of
errors committed by memory-impaired aged rats under
drug-free condition as described above.
In Situ Hybridization
At the end of the NPY experiment, the brains of the rats
were harvested following perfusion. A riboprobe template
targeting the FIB NPY 13–36 sequence was generated by
PCR from rodent whole hippocampus RNA and modified to
contain SP6 and T7 RNA polymerase sites. 35S-UTP-labeled
riboprobe was generated using the Maxiscript kit (Ambion).
Brain sections (40 mm) from across the entire extent of the
hippocampus were hybridized overnight at 601C in buffer
containing the radiolabeled riboprobe. Hybridized sections
were then extensively washed and mounted onto slides.
RESULTS
Background Assessment of Cognitive Status
Rats were tested for cognitive status before the intervention
experiments using a protocol developed in this study
population. Figure 1 shows the mean learning index of
memory-impaired aged rats (n¼ 67) subsequently used in
the current experiments, and for comparison, the learning
index of young rats (n¼ 122) that were tested concurrently
with these aged rats during background characterization.
Higher learning index scores signify worse performance by




















Figure 1 Background behavioral characterization. The cognitive status of
aged and young rats was assessed in a standardized water maze task before
intervention experiments. Higher learning index scores signify worse
performance by reflecting search at a greater distance from the escape
location during memory probe tests. Aged rats that performed beyond the
normative range of young adult rats in this study population were selected
for the present studies. *p¼ 0.001.
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location during memory probe tests. As only aged rats that
performed beyond the normative range of young adult rats
in this study population were selected for the subsequent
experiments, it is not surprising that the performance of
these aged rats was significantly impaired relative to the
young rats, t(187)¼ 13.97, p¼ 0.001.
Spatial Memory Under AAV–NPY Treatment
Rats were assigned to treatment groups based on the
background characterization (mean learning indexes were
273 (SEM¼ 14.5) and 279 (SEM¼ 14.7) for experimental
and control groups, respectively). Two weeks after NPY or
control injection, aged rats were trained and tested in a
novel water maze environment. Figure 2a shows the average
escape latencies over four blocks of training trials (three
trials per block). An analysis of variance (ANOVA) with
repeated measures showed significant improvement over
the course of training as indicated by decreased escape
latencies in a main effect of Trial Block, F(3, 30)¼ 3.24,
p¼ 0.036. Rats in the NPY group also showed significantly
better performance than the age/impairment-matched
control group as indicated by a significant group effect,
F(1, 10)¼ 6.28, p¼ 0.031. Even though the group  trial
block interaction was not significant, F(3, 30)¼ 1.12,
p¼ 0.358, the overall better performance of the NPY group
was not evident on the first training trial, t(10)¼ 0.537,
p¼ 0.603. The group difference in escape latencies was also
not because of swim speed performance because there was
no significant difference on that measure during training
trials for rats in the two groups (NPY¼ 17.1 cm/s,
SEM¼ 1.37; control¼ 15.6 cm/s, SEM¼ 2.48).
A probe test was subsequently given 24 h after training in
which the escape platform was removed. As expected for
aged rats characterized with impairment, the control group
showed no evidence of memory, searching a similar amount
of time in all quadrants of the maze (Figure 2b). In contrast,
the NPY group showed retention for the escape platform
location as indicated by a strong spatial bias for the target
quadrant. An ANOVA with repeated measures showed a
marginally significant group  quadrant interaction over-
all, F(3, 30)¼ 2.91, p¼ 0.051. Further analysis confirmed
that rats in the NPY group showed a spatial bias for the
target quadrant, t(5)¼ 2.86, p¼ 0.035 (compared with the
average search in the other quadrants). In contrast, that
analysis showed no significant spatial bias in the perfor-
mance of rats in the control group, to1. Finally, rats in the
NPY group spent significantly more time in the target
quadrant compared with those in the control group,
t(10)¼ 2.33, p¼ 0.042.
Photomicrographs of hippocampal sections of aged
rats in the NPY group confirmed that FIB–NPY 13–36
mRNA was present in the area of AAV injection (Figure 3),
whereas control brains showed absence of specific probe
hybridization.
VPA Treatment on Memory Performance in the Water
Maze Task
The effect of chronic treatment with the antiepileptic drug,
VPA, was assessed in separate groups of aged rats
implanted with osmotic mini-pumps as described in
Materials and methods section (50 mg/kg, n¼ 9; 100 mg/
kg, n¼ 13; vehicle treatment, n¼ 17). Group assignment
was matched for learning index scores (291 (SEM¼ 10.8),
290 (SEM¼ 5.4), and 297 (SEM¼ 7.7) for VPA 50 mg/kg,
VPA 100 mg/kg, and vehicle groups, respectively). In this
study, rats were trained to new spatial locations in each
day’s training session and a retention test occurred at a 6 h
delay. Figure 4 shows the path length (a) and escape latency
(b) data for rats that received treatment of vehicle (VEH),
VPA at 50 mg/kg/day (VPA 50), or VPA at 100 mg/kg/day
(VPA 100) averaged over three new escape locations.
During training, rats in all three groups improved within
the day’s session, attaining similar proficiency in perfor-
mance by the last training trial. For path length, an ANOVA
with repeated measures showed a significant main effect of
trial, F(5, 180)¼ 19.94, p¼ 0.001. There was also a main
effect of group, F(2, 36)¼ 4.02, p¼ 0.027, reflecting some-
what longer paths in rats that received VPA at 50 mg/kg
relative to the groups that received vehicle or VPA at
100 mg/kg. The three groups however were not different
from each other at the end of training, p40.304 (Trial 6).
Similar results were obtained in the analysis of escape
latency. Rats took progressively less time to escape over
















































Figure 2 Behavioral assessment of NPY treatment. Memory-impaired aged rats that received AAV–NPY 13–36 injections into the CA3 of the
hippocampus 2 weeks before, performed better than control rats during water maze training (a), and showed stronger memory retention for the escape
platform location in a probe trial 24 h after training (b). See text for details of data analysis.
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differences, F(2, 36)¼ 2.81, p¼ 0.073, but no performance
difference among the groups at the end of training sessions,
p40.661.
The rats were given a retention trial after a 6-h delay to
assess memory of the previous session’s learning. Better
retention was evident in rats treated with VPA at 100 mg/kg/
day for both escape latency and path. A one-way ANOVA
indicated a significant group effect, F(2, 36)¼ 4.258,
p¼ 0.022 for path length, and F(2, 36)¼ 7.606, p¼ 0.002
for escape latency. Further group comparisons confirmed
that rats in the VPA 100 group had significantly shorter
path lengths and escape latencies than those in the VEH and
VPA 50 groups (all p-values o 0.05). The VEH and VPA 50
groups were not different from each other on either
measure, p-values 40.927. Taken together, these results
indicate that chronic VPA treatment dose-dependently
improves retention of new spatial information in aged rats
previously characterized with hippocampal-dependent cog-
nitive impairment.
VPA, LEV, and Combination Therapy on the Radial Arm
Maze Task
To further assess the effects of antiepileptic drugs in aged
impaired rats, we used a radial arm maze task that allowed a
within-subject design to compare two different compounds,
VPA and LEV. This task also extended the behavioral
assessment to spatial memory using appetitive motivation.
An independent set of aged rats (n¼ 10), which were
characterized with impairment in the background water
maze assessment (mean learning index¼ 266, SEM¼ 7.1)
served as subjects. Figure 5 shows the memory performance
of those rats treated with varying doses of VPA by
subcutaneous (s.c.) injection and LEV by intraperitoneal
(i.p.) injection as indexed by the number of errors made
during post-delay memory tests. Differences in memory
performance were evident under VPA treatment as a
function of dose, F(4, 32)¼ 2.87, p¼ 0.039. The VPA doses
at 100 and 200 mg/kg significantly reduced errors relative to






Figure 3 AAV–NPY transduction in the hippocampus. Photomicrographs of coronal hippocampal sections of aged rats showing FIB–NPY 13–36 mRNA
(right panel) was present in the NPY group, and the absence of specific probe hybridization in the brain of a control rat (left panel). In testing for the FIB–











































Figure 4 VPA assessment in the water maze. Memory-impaired aged rats that received chronic treatment with VPA or saline performed at a comparable
level at the end of the water maze training phase (Trial 6), but those treated with VPA at 100 mg/kg/day (VPA 100) showed less forgetting as measured by
path length (a) and escape latency (b) after a 6-h delay (Retention Trial) compared with their counterparts treated with saline (VEH) or VPA at 50 mg/kg/day
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Figure 5 VPA and LEV assessment in the radial maze. Efficacious doses
of VPA and LEV to improve memory performance of aged rats with
cognitive deficit were determined using a within-subject design in an eight-
arm radial maze. Over the course of the study, the same rats were tested
repeatedly with vehicle saline (0 mg/kg), VPA, and LEV. Post-delay memory
errors were significantly lower than vehicle baseline when rats were treated
with VPA at 100 and 200 mg/kg, as well as with LEV at 5 and 10 mg/kg.
*po0.050 and #p¼ 0.051 compared to vehicle treatment (0 mg/kg).
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respectively. LEV also appeared to decrease errors in the
post-delay tests. An overall analysis of LEV administration
in the aged rats revealed differences in performance as a
function of dose, F(5, 45)¼ 2.38, p¼ 0.053, with rats making
fewer errors on 5 and 10 mg/kg of LEV compared with
saline, t(9)¼ 3.53, p¼ 0.006 and t(9)¼ 2.25, p¼ 0.051,
respectively. These results therefore confirm the initial
findings in the water maze with VPA, extend the improve-
ment seen with that treatment to an appetitive spatial
memory task, and suggest that another antiepileptic drug,
LEV, has similar benefit in a low-dose range.
We also tested combinations of LEV and VPA at sub-
threshold doses (when administered individually) to assess
the possibility that these drugs might improve memory
when given in combination. Before those drug tests, we first
re-established baseline performance with a combination of
i.p and s.c. saline injections. Figure 6a shows the results of
combination doses and the comparison vehicle treatment.
Compared with vehicle, the combination of VPA 50 mg/kg
and LEV 2.5 mg/kg, as well as the combination of VPA
50 mg/kg and LEV 1.25 mg/kg, were effective at significantly
reducing memory errors, t(7)¼ 2.49, p¼ 0.042, and
t(7)¼ 2.68, p¼ 0.032, respectively. The combination of
VPA 25 mg/kg and LEV 2.5 mg/kg, however, did not differ
from vehicle. We plotted those data in an isobologram. As
indicated in the isobologram (Figure 6b), the dose
combination of VPA 50 mg/kg and LEV 1.25 mg/kg falls
below the line/isobole of additivity, suggesting super-
additive or synergistic interaction between VPA and LEV
in that combination of doses.
LEV Treatment on Memory Performance in the Water
Maze Task
In a final experiment, acute treatment with LEV at 10 mg/kg
was given to impaired aged rats (n¼ 6; mean learning
index¼ 280, SEM¼ 6.6) during water maze training using a
within-subject design to compare drug performance with
saline. Hence upon completion of assessing the first
treatment condition (drug or vehicle, counterbalanced),
the rats received the other treatment starting the next day in
the same maze but surrounded by a new set of curtains with
a novel configuration/color of cues, and a new escape
platform location. Figure 7a shows performance during
training trials. An ANOVA with repeated measures revealed
that the rats improved during training as their escape
latencies significantly decreased over trials, F(3, 15)¼ 5.58,
p¼ 0.009. Although performance appears better under drug
than saline at the end of training, no statistical difference
was revealed involving treatment; that is, no significant
treatment  trial block interaction (p40.25) or main
treatment effect (p40.60).
A memory probe test was given 24 h after the end of
training (data in Figure 7b). An ANOVA with repeated
measures showed a strong trend for a treatment 
quadrant interaction, F(3, 15)¼ 3.14, p¼ 0.057, in which
LEV treatment during training augmented subsequent
retention for the escape platform location. A spatially
localized search was evident in time spent in the target
quadrant, which was significantly greater when rats had
been treated with LEV compared with saline, t(5)¼ 2.80,
p¼ 0.038. Overall then, these results indicate that LEV
treatment at 10 mg/kg benefits long-term spatial memory in
aged rats that are otherwise impaired.
LEV Treatment on Memory Performance in Young Rats
On the basis of our hypothesis of targeting excess
hippocampal activity, we expected that these treatments
might only benefit aged rats but not young rats. In a study
run in parallel with the aged rats, injection of AAV–NPY
into the CA3 of young rats (6 months old) produced no
improvement in the water maze performance beyond that
of control rats (data not shown). That study however was
limited by strong memory performance in the young
control rats, thus possibly precluding the detection of
improvement in the experimental treatment group. To
address that limitation, we ran a separate study with a new
batch of young rats using the radial arm maze and imposing
a lengthy delay between information and test phase (5-h
delay) to attain a number of errors similar to those of aged
rats at the shorter delay. Before treatment, these young rats
had received the same background water maze assessment


































































Figure 6 Combination VPA/LEV assessment in the radial maze. Combination therapy consisting of VPA and LEV was assessed in the radial arm maze after
each drug was tested individually over a range of doses. (a) Baseline performance was established with combination saline injections, and sub-threshold doses
of each drug (VPA at 25 or 50 mg/kg, and LEV at 1.25 or 2.5 mg/kg) were administered in combination. To facilitate interpretation, effective combinations
were then plotted on an isobologram (b). The diagonal straight line is the line of additivity, anchored on each axis by the lowest effective doses of VPA and
LEV when assessed individually. Efficacious combinations at lower sub-threshold doses that fall on the line are interpreted accordingly as a simple additive
effect, as is the case for the treatment of VPA 50 mg/kg combined with LEV 2.5 mg/kg. The dose combination of VPA 50 mg/kg and LEV 1.25 mg/kg falls
below the line of additivity, suggesting super-additive or synergistic interaction between the two drugs.
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They were then tested on the radial arm maze with a series
of LEV doses in the same fashion as that in the aged rat
study. Figure 8 shows the memory performance of young
rats treated with varying doses of LEV as indexed by the
number of errors made during post-delay memory tests. No
significant differences in performance were found as a
function of dose, F(5, 35)¼ 0.46, p¼ 0.806. These data
indicate that this pharmacological treatment aimed at
reducing excess hippocampal activity only benefits memory
performance in aging.
DISCUSSION
The studies reported here were designed to test the
hypothesis that excess neural activity in the hippocampus
of aged rats contributes to memory impairment. We first
overexpressed an inhibitory neuropeptide (NPY 13–36)
targeting the CA3 region of the hippocampus of aged rats
using methods shown to attenuate aberrant excitability in
limbic seizure models. We also tested two widely used
antiepileptic agents administered systemically. In each case,
aged rats with established memory impairment showed
improved behavioral performance in spatial memory tasks.
The converging evidence for benefits of these treatments
indicates that excess excitation in the hippocampus may
have a key role underlying age-related impairment in
hippocampal-dependent memory processes as proposed for
this model (Wilson et al, 2006).
Aged rats in the current research came from a study
population with well-characterized individual differences in
memory impairment. Importantly, previous studies have
shown a high degree of test-retest reliability for the presence
and severity of those individual differences in behavioral
assessments; aged rats that fall outside the range of
normative young performance in the standardized assess-
ment show a similar behavioral profile in subsequent tests
of hippocampal-dependent memory (Colombo et al, 1997;
Robitsek et al, 2008). Such evidence increases confidence
that the assignment of subjects based on the standardized
background assessment ensured a valid test of treatment
efficacy in experiments using between group comparisons.
In addition, the data obtained in the experiments using
within-subject designs support the reliability of individual
differences because impairment was routinely evident
under vehicle treatment in those studies, as discussed
further below.
The hypothesis examined here is also grounded in much
background research in this model showing that behavioral
status in the aged rat study population is strongly correlated
with neurobiology in the underlying circuitry of the
hippocampal formation. Although aged rats in this study
population maintain similar number of neurons and largely
preserved synaptic connections in the medial temporal lobe
system (Geinisman et al, 2004; Rapp and Gallagher, 1996;
Rapp et al, 2002; Smith et al, 2000), functional alterations
are closely tied to age-related cognitive decline. The striking
increase in neural activity in the CA3 region led to a
proposal for the basis of cognitive impairment, which links
that excess activity to loss of encoding that normally
depends on the CA3/dentate gyrus subdivisions of the
hippocampal network (Wilson et al, 2006). As the majority
of synaptic input to the CA3 pyramidal neurons comes from
the excitatory recurrent CA3 collaterals, elevated activity
would be expected to promote pattern completion, a
computational function attributed to the CA3 autoassocia-
tive network that favors retrieval of previously stored
representations (Guzowski et al, 2004; Treves and Rolls,
1994). In addition, the joint occurrence of elevated activity


















































Figure 7 LEV assessment in the water maze. Memory-impaired aged rats were injected with LEV at 10 mg/kg or saline vehicle before training in the water
maze (a). Better memory retention was observed under LEV than saline treatment 24 h later in a probe test (b). *po0.050 compared with percent time
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Figure 8 LEV treatment in young rats. Young rats were treated with LEV
at varying doses before testing in the radial arm maze using a 5-h retention
delay. No differences in memory performance were found as a function of
dose.
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networks, including the hippocampus; synaptic plasticity
most readily occurs in an optimal range of activity, and
thresholds for synaptic modification can rise in conditions of
excess activity (see Abraham et al, 2001 for example, and
Abraham, 2008 for recent review). Recording data from
hippocampal neurons in this study population are in
agreement with this concept linking excess activity to a failure
to encode new information in the CA3 network (Wilson et al,
2005). By that view, experimental treatments that lower activity
would be expected to lower the threshold for synaptic
modification to allow the encoding of new information.
As an initial test of this idea, we locally expressed an
inhibitory neuropeptide, NPY13–36, which has been shown
elsewhere to be effective in modulating neuronal excitability
under both normal and epileptic conditions (Foti et al,
2007; McQuiston and Colmers, 1996; Vezzani et al, 1999).
NPY13–36 preferentially activates the Y2 receptor subtype
which has a predominant role in mediating the NPY-
induced inhibition of glutamate release in the CA1 and CA3
of the hippocampus (El Bahh et al, 2005; Silva et al, 2005).
We engaged the inhibitory property of Y2 receptor
activation by constitutively expressing NPY 13–36 via an
AAV vector delivered into the CA3; this resulted in
significantly improved hippocampal-dependent memory in
the aged rats. In situ histochemistry for the vector-produced
mRNA confirmed that expression of NPY13–36 was
restricted to the hippocampus and centered primarily on
the CA3, likely providing only local control of inhibition in
that area. Because no elevated activity is observed in the
CA1 subregion of the hippocampus in our aging model
(Wilson et al, 2005), and CA3 connections (Shaffer
collaterals) onto CA1 neurons have reduced efficacy in the
aged brain (Lister and Barnes, 2009), boosting inhibition in
the adjacent CA1 area would not be expected to have
beneficial effects on network function. These data therefore
support the view that controlling excess neural activity in
the CA3 of aged rats improves hippocampal network
function and hippocampal-dependent memory perfor-
mance, and serves as a proof of principal for further
exploration into more clinically accessible methods of
modulating excess neural activity.
Subsequent tests centered on the same rationale of
targeting excess excitation by administering two widely
used antiepileptic agents, VPA and LEV, which each showed
the ability to improve spatial memory in aged rats. In the
first of those studies, VPA was assessed in a spatial memory
task when aged memory-impaired rats learned new escape
platform locations in each day’s session in the water maze.
Rats implanted with osmotic mini-pumps to administer
100 mg/kg had substantial savings after a 6 h delay, escaping
with similar proficiency relative to the end of the previous
session’s training trials. Those rats differed from the control
vehicle group and a group receiving a lower dose of VPA,
which showed little savings for previous training after the
delay. In a subsequent study using a within-subject design,
VPA doses of 100 and 200 mg/kg significantly improved
memory performance on the radial maze after a 1-h delay.
The improvement obtained with effective doses of VPA
reduced errors to levels typically seen in young rats tested
on this task (Chappell et al, 1998). Together those
experiments show a benefit from VPA treatment across
spatial memory tasks with different motivational and
performance demands. It is important to note that blood
levels of VPA in rats at the doses effective for neurocog-
nitive aging (10 mg/ml; see Materials and methods section
for details) are well below those needed for antiepileptic
efficacy to control seizure activity (225 mg/ml and above;
Tulloch et al, 1982). Indeed, high dosing might be less
effective for cognitive improvement in aging by producing
more pronounced and widespread effects on brain function.
Similar to VPA, LEV was also found to improve memory
performance on the radial maze at doses substantially lower
than those used in seizure models. Significant improvement
was observed at 5 and 10 mg/kg, but not at a higher dose
of 20 mg/kg. Typical antiepileptic doses of LEV in rodent
seizure models are in a range of 50–150 mg/kg (eg, Ji-qun
et al, 2005; Stratton et al, 2003). In addition, the two
antiepileptic compounds VPA and LEV exhibited benefit in
combination at doses that were otherwise ineffective.
Comparing the dose response for the individual drugs with
the combinations provided evidence for drug synergy rather
than merely additive effects. As an extension of the data
obtained in the radial maze, improved retention over a 24 h
delay was confirmed with LEV at 10 mg/kg in an
independent set of memory-impaired aged rats trained in
a novel water maze environment. Finally, as expected under
the view that benefit is because of dampening excess
activity, we found no improvement in memory performance
when young adult rats were given LEV.
Although the route by which VPA and LEV exert
antiepileptic efficacy is not known with certainty, and those
mechanisms may not directly apply to the doses used in the
current studies, these two compounds share little apparent
mechanistic overlap. The efficacy of VPA as an antiepileptic
potentially involves a variety of mechanisms, including
increased g-amino butyric acid (GABA)-ergic transmission,
increased uptake of excitatory amino acids, and blockade of
voltage-gated sodium channels (Perucca, 2002). At the low
doses found to be effective in the current research, the most
likely mechanisms involve control of excitatory transmis-
sion by reducing extracellular accumulation of glutamate
and increased GABAergic transmission. An upregulation of
hippocampal glutamate transport occurs in rats treated with
VPA (Hassel et al, 2001). We confirmed this finding at doses
used in our aged rats and further observed that low doses of
VPA administered systemically increase the hippocampal
expression of GLT1b, an isoform of the glutamate
transporter (M Gallagher, unpublished data). In contrast
to the localization of GLT1a in astrocytes, GLT1b is
localized to neurons in association with the post-synaptic
density (González-González et al, 2008). Thus, VPA may
permit the regulation of excitatory transmission at synapses
that drive neuron activity in addition to boosting inhibition.
LEV is thought to mediate its effects via a synaptic vesicle
protein Sv2a, which renders primed synaptic vesicles
competent for activity-dependent (calcium-mediated)
release (Chang and Südhof, 2009). At concentrations of
up to 10 mM, LEV does not show binding affinity for
a variety of known receptors, such as those associated with
benzodiazepines, GABA, glycine, and NMDA (N-methyl-
D-aspartate). In vitro and in vivo recordings of epilepti-
form activity from the hippocampus have shown that
LEV inhibits burst firing. In vivo data also show that
LEV opposes a pilocarpine-induced increase of the
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orthodromically activated population spike in the CA3 region
of hippocampus (Klitgaard et al, 2003). Synergistic activity
has also been noted for use of VPA and LEV in combination
in studies of seizure models (Kaminski et al, 2009).
Current data suggest that modifying excitatory–inhibitory
balance through different routes can ameliorate behavioral
memory impairment in aging. The benefit observed with
these different treatments suggests that neural activity and
encoding properties in the hippocampal network are
ameliorated by targeting excess activity. Studies to directly
monitor such effects, using electrophysiological recordings
in awake behaving rats, are beyond the scope of the current
investigation, but will be informative as to whether such
restoration is a final common pathway for behaviorally
effective treatments in this model.
The functional significance of aberrant activity in the
hippocampus may not be limited to animal models of aging
but may also have direct implications for memory decline
experienced during aging in humans. A number of
investigations using functional neuroimaging in human
aging have reported increased activation in the medial
temporal lobe during memory encoding. This finding has
now been observed in patients with mild cognitive impair-
ment (MCI; Celone et al, 2006; Dickerson et al, 2004;
Dickerson et al, 2005; Hämäläinen et al, 2007), in older
individuals with genetic or familial risk for developing
Alzheimer’s disease (Bassett et al, 2006; Bookheimer et al,
2000), and in aged subjects showing poor performance in
memory but not sufficiently impaired to meet a diagnosis of
MCI (Miller et al, 2008a). The original view of such increased
activation was that it served a beneficial function by
recruiting additional resources to provide ‘compensation’
for a failing neural network. A possible detrimental role of
excess activation in humans, however, has been suggested by
findings in follow up with MCI patients (Dickerson et al,
2004; Miller et al, 2008b). Specifically, Miller and colleagues
(2008b) found that higher activation in the hippocampus,
but not in signals imaged elsewhere in the brain, predicted
greater subsequent cognitive decline 4–8 years after initial
evaluation. Consequently, those authors suggested that
elevated hippocampal activation might serve as a therapeutic
target for early intervention in cognitive decline. An
assessment of whether reduction in elevated hippocampal
activation in humans leads to worse memory performance,
as suggested by a compensation view, or improves
performance, consistent with the animal data obtained here,
would provide a needed experimental test of the alternative
interpretations now existing in the clinical literature. If the
condition in humans’ parallels the excess activity observed
in studies of aged animals with memory impairment, such a
test would be feasible using FDA approved compounds
(VPA and LEV) that are effective in aged animals, albeit at
lower doses than those used for other clinical indications.
Not much more than a decade ago it was widely believed
that loss of neurons in the brain was the cause of memory
impairment associated with aging. Now it is generally
accepted that memory decline is predominantly a functional
disorder in aged brains that are largely structurally intact.
This view gives hope to the prospect for corrective therapies
that will aid in the restoration of function in the aged brain.
Many recent approaches to this problem have focused on
boosting mechanisms underlying neural plasticity in young
adults (Josselyn and Nguyen, 2005; Rose et al, 2005 for
reviews). The current research supports a novel approach
based on a disorder specific to the condition of neurocogn-
tive impairment in the aged brain. As such, the findings
may point to novel targets for therapies in this indication.
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